Guided Therapeutics (GTHP) Total Current Liabilities (2016 - 2025)
Guided Therapeutics' Total Current Liabilities history spans 16 years, with the latest figure at $6.6 million for Q4 2025.
- On a quarterly basis, Total Current Liabilities rose 7.81% to $6.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 million, a 7.81% increase, with the full-year FY2025 number at $6.6 million, up 7.81% from a year prior.
- Total Current Liabilities hit $6.6 million in Q4 2025 for Guided Therapeutics, up from $6.5 million in the prior quarter.
- Over the last five years, Total Current Liabilities for GTHP hit a ceiling of $9.2 million in Q1 2021 and a floor of $4.0 million in Q1 2023.
- Historically, Total Current Liabilities has averaged $5.7 million across 5 years, with a median of $5.7 million in 2021.
- Biggest five-year swings in Total Current Liabilities: crashed 40.96% in 2022 and later skyrocketed 33.45% in 2024.
- Tracing GTHP's Total Current Liabilities over 5 years: stood at $5.7 million in 2021, then fell by 14.49% to $4.9 million in 2022, then decreased by 1.23% to $4.8 million in 2023, then increased by 27.99% to $6.2 million in 2024, then rose by 7.81% to $6.6 million in 2025.
- Business Quant data shows Total Current Liabilities for GTHP at $6.6 million in Q4 2025, $6.5 million in Q3 2025, and $6.4 million in Q2 2025.